Oncotarget

Corrections:

Correction: A randomized phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinumbased chemotherapy in advanced nonsmall cell lung cancer KCSG LU1201

PDF  |  How to cite

Oncotarget. 2017; 8:55766-55766. https://doi.org/10.18632/oncotarget.20268

Metrics: PDF 2784 views

Present: The current funding information is incomplete.

Corrected: The complete funding information is given below.

Original article: Oncotarget. 2017; 8:15943-51. DOI:https://doi.org/10.18632/oncotarget.13056.

FUNDING

This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.).